Ambulero
Khemraj Hirani is the Chief Regulatory Officer at Ambulero.
Khemraj has 21 years of investigational drugs/biologics experience from bench to clinic. Principal strategic and regulatory consultant for clinical, scientific, and regulatory SME for the University of Miami Miller School of Medicine, PriZm Therapeutics, IGEA Pharma, Betalin Therapeutics, Eyepharma Inc, AAHRPP. Certified clinical (RPH), IRB (CIP), and Regulatory (RAC-US) professional dedicated to bringing novel therapies to market for unmet medical conditions.
This person is not in any offices
Ambulero
Ambulero is a cell and gene therapy spin-out of the University of Miami focused on advancing new therapies to fight vascular disease. A platform company that can deliver the adhesion molecule E-selectin using different cell and synthetic vector technologies.